Ovarian Vein Embolization With N-butyl-2 Cyanoacrylate Glubran-2® for the Treatment of Pelvic Venous Disorder
Authors:
Open Access
- 16 December 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 8, 760600
Abstract
Background: There are few reports in the literature on the use of Glubran-2 for the embolization of ovarian veins in patients with pelvic venous disorder (PeVD). In addition, a consensus on the efficacy and safety of Glubran-2 has not been reached.Purpose: To investigate the safety and efficacy of ovarian vein embolization (OVE) with N-butyl-2 cyanoacrylate (NBCA) Glubran-2 for the treatment of PeVD.Material and Methods: Between January 2013 and January 2020, 21 women (mean age, 43.9 ± 13.3 years) with PeVD who underwent OVE with Glubran-2 were evaluated. Of those patients, ovarian vein or pelvic venous plexus insufficiency was verified by duplex ultrasound and/or multislice computer tomography (MSCT). The symptoms and signs of PeVD included chronic pelvic pain (CPP) (21/21; 100%), dyspareunia (12/21; 57.1%), dysmenorrhea (10/21; 47.6%), and vulvar varices (3/21; 14.3%). The medical data were retrospectively reviewed.Results: Glubran-2 was employed as the sole embolic material in 18 cases (85.7%) and used to perform rescue embolization in 3 cases (14.3%) due to CPP recurrence 1 month after initial embolization using microcoils. Technically successful embolization was achieved using Glubran-2 in all patients. No Glubran-2 related complications were noted. Neither persistent nor recurrent CPP was observed during follow-up, for which the mean was 62 ± 38 months (range, 12–102 months). Clinical efficacy was evaluated, and all patients exhibited complete or slight improvement of CPP after embolization. The visual analog scale (VAS) score significantly decreased from pre-intervention to post-intervention (p < 0.001). Six patients (28.6%) gave birth to healthy babies during follow-up after embolization with Glubran-2.Conclusions: Ovarian vein embolization with Glubran-2 is a feasible and safe treatment for CPP secondary to PeVD. This treatment may represent a potential and attractive alternative when patients desire symptom relief and want to continue reproducing. Larger studies are warranted to confirm the findings of this study.Keywords
This publication has 25 references indexed in Scilit:
- Hypersensitivity to nickel in a patient treated with coil embolization for pelvic congestion syndromeJournal of Vascular Surgery: Venous and Lymphatic Disorders, 2015
- Clinical outcome after treatment of pelvic congestion syndrome: Sense and nonsensePhlebology: The Journal of Venous Disease, 2015
- Trans-venous occlusion of incompetent pelvic veins for chronic pelvic pain in women: a systematic reviewEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2015
- Embolization to treat pelvic congestion syndrome and vulval varicose veinsInternational Journal of Gynecology & Obstetrics, 2012
- The care of patients with varicose veins and associated chronic venous diseases: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous ForumJournal of Vascular Surgery, 2011
- Quality Improvement Guidelines for Percutaneous Transcatheter EmbolizationJournal of Vascular and Interventional Radiology, 2010
- Research Reporting Standards for Endovascular Treatment of Pelvic Venous InsufficiencyJournal of Vascular and Interventional Radiology, 2010
- Evaluation of Transcatheter Arterial Embolization with Gelatin Sponge Particles, Microcoils, and N-butyl Cyanoacrylate for Acute Arterial Bleeding in a Coagulopathic ConditionJournal of Vascular and Interventional Radiology, 2009
- Transcatheter Ovarian Vein Embolization Using Coils for the Treatment of Pelvic Congestion SyndromeCardioVascular and Interventional Radiology, 2007
- Embolotherapy for Pelvic Congestion Syndrome: Long-term ResultsJournal of Vascular and Interventional Radiology, 2006